Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

It's A List! Why Is China's Rare Disease List A Major Milestone For Orphan Drug Developers?

Executive Summary

Largely different from the US and EU, China is tackling rare diseases with a first-ever official list of 121 conditions for now, which could be a major milestone for orphan drug developers, some experts say.

You may also be interested in...



Eight For 8: Things You Need To Know About China Biopharma Regulation In 2018

The Pink Sheet's pick of eight major events that captured major regulatory developments in China’s dynamic, highly fluid biopharma scene in 2018.

Rare Diseases: What Makes China A Rising Star?

Top corporate executives are increasingly turning their attention to rare diseases in China as changing regulatory policies provide a rare opening, and aided by more physicians advocating for orphan drug access. What does the first ever report on rare diseases in China have to say about the opportunities and challenges?

Cancer, Orphan, Pediatric Drug Developers Join China Foreign Data Acceptance Party

China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel